Please assess the completion status of the following clinical trial:

Trial Title: Androgen Deprivation Therapy Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men 18 years of age or older with prostate cancer~* Planning to undergo long-term (at least 12 months) ADT~* No known history of diabetes~* No history of ADT~Exclusion Criteria:~* History of ADT or any prior diagnosis of hypogonadism~* Fasting glucose or oral glucose tolerance test results in the diabetic range~* Heart failure (NY classification III or IV)~* Testosterone level less than 250 ng/dl on screening~* History of heart attack or open-heart surgery within the past 6 months~* Use of steroids within the past 3 months, including prednisone, cortisone injections, inhaled steroids (topical steroids are acceptable)~* Use of anabolic steroids (testosterone, DHEA, DHEAS) or any growth promoters (growth hormone itself or analogs of growth hormone) in the past 12 months~* Liver function tests more than 3 times upper normal limits~* Undergoing intermittent ADT~* Uncontrolled thyroid disease (hyper- or hypo-thyroidism)~* Anemia, defined as hematocrit less than 38%~* Not physically capable of completing the tests

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Participants receiving ADT and pioglitazone
- 2 (Type: None): Participants receiving ADT only
- 3 (Type: None): Participants not receiving ADT and in remission from prostate cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).